OCGN - Ocugen, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Malvern,
United States
Type: Equity
OCGN price evolution
OCGN
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $16 | $26.38 | $39.46 | |
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $40.67 | $18.62 | $30 | $42.97 |
| Long term investments | ||||
| Property, plant & equipment | $17.13 | $17.47 | $17.65 | $17.29 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $21.93 | $21.8 | $21.58 | |
| Total investments | ||||
| Total assets | $61.94 | $40.54 | $51.79 | $64.55 |
| Current liabilities | ||||
| Accounts payable | $1.49 | $3.39 | $1.73 | $3.17 |
| Deferred revenue | ||||
| Short long term debt | $1.77 | $1.89 | $0.57 | |
| Total current liabilities | $15.76 | $17.97 | $16.05 | $17.09 |
| Long term debt | $1.57 | $5.1 | $4.95 | $6.37 |
| Total noncurrent liabilities | $5.64 | $5.48 | $6.89 | |
| Total debt | $6.87 | $6.83 | $6.94 | |
| Total liabilities | $21.31 | $23.61 | $21.53 | $23.98 |
| Shareholders' equity | ||||
| Retained earnings | -$326.34 | -$313.37 | -$298.09 | -$286.17 |
| Other shareholder equity | $0.02 | $0.03 | $0.03 | $0.02 |
| Total shareholder equity | $16.93 | $30.26 | $40.56 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $39.46 | $77.56 | $95.11 | $24.19 |
| Short term investments | $13.37 | |||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $42.97 | $98.49 | $102.65 | $25.88 |
| Long term investments | ||||
| Property, plant & equipment | $17.29 | $9.96 | $1.16 | $0.63 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $21.58 | $10.14 | $3.12 | $1.5 |
| Total investments | $13.37 | |||
| Total assets | $64.55 | $108.63 | $105.76 | $27.38 |
| Current liabilities | ||||
| Accounts payable | $3.17 | $8.06 | $2.31 | $0.4 |
| Deferred revenue | ||||
| Short long term debt | $0.57 | $0.5 | $0.36 | $0.28 |
| Total current liabilities | $17.09 | $18.46 | $7 | $3.61 |
| Long term debt | $6.37 | $2.29 | $2.94 | $2.21 |
| Total noncurrent liabilities | $6.89 | $6.12 | $2.94 | $2.21 |
| Total debt | $6.94 | $6.37 | $3.31 | $2.49 |
| Total liabilities | $23.98 | $24.58 | $9.94 | $5.83 |
| Shareholders' equity | ||||
| Retained earnings | -$286.17 | -$213.02 | -$131.67 | -$73.3 |
| Other shareholder equity | $0.02 | $0.03 | -$0.05 | |
| Total shareholder equity | $40.56 | $84.05 | $95.82 | $21.55 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1.14 | $1.01 | $6.04 | |
| Cost of revenue | ||||
| Gross Profit | $1.14 | $1.01 | $6.04 | |
| Operating activities | ||||
| Research & development | $8.9 | $6.83 | $9.5 | |
| Selling, general & administrative | $7.69 | $6.4 | $5.16 | |
| Total operating expenses | $16.59 | $13.23 | $14.66 | |
| Operating income | -$15.45 | -$12.22 | -$8.62 | |
| Income from continuing operations | ||||
| EBIT | -$15.28 | -$11.92 | -$9.49 | |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$15.28 | -$11.92 | -$9.49 | |
| Income (for common shares) | -$10.29 | -$11.92 | -$9.49 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $6.04 | $0.04 | ||
| Cost of revenue | ||||
| Gross Profit | $6.04 | $0.04 | ||
| Operating activities | ||||
| Research & development | $39.57 | $49.76 | $35.11 | $6.35 |
| Selling, general & administrative | $31.99 | $35.11 | $22.92 | $7.97 |
| Total operating expenses | $71.57 | $84.87 | $58.03 | $21.33 |
| Operating income | -$65.53 | -$84.87 | -$58.03 | -$21.28 |
| Income from continuing operations | ||||
| EBIT | -$63.08 | -$81.35 | -$58.34 | -$21.1 |
| Income tax expense | -$0.05 | |||
| Interest expense | $0.08 | $0.72 | ||
| Net income | ||||
| Net income | -$63.08 | -$81.35 | -$58.37 | -$21.82 |
| Income (for common shares) | -$63.08 | -$81.35 | -$58.37 | -$34.37 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$15.28 | -$11.92 | -$9.49 | |
| Operating activities | ||||
| Depreciation | $0.67 | $0.32 | $0.32 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $1.9 | $1.76 | $1.72 | |
| Total cash flows from operations | -$9.91 | -$10.6 | -$11.3 | |
| Investing activities | ||||
| Capital expenditures | -$0.51 | -$2.35 | -$2.72 | |
| Investments | ||||
| Total cash flows from investing | -$3.37 | -$0.51 | -$2.35 | -$2.72 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.04 | -$0.14 | $0.02 | |
| Net borrowings | ||||
| Total cash flows from financing | $34.69 | $0.04 | -$0.14 | $0.02 |
| Effect of exchange rate | $0 | $0 | $0.01 | -$0.01 |
| Change in cash and equivalents | -$0.46 | -$10.38 | -$13.09 | -$14.02 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$63.08 | -$81.35 | -$58.37 | -$21.82 |
| Operating activities | ||||
| Depreciation | $1.24 | $1.07 | $0.59 | $0.29 |
| Business acquisitions & disposals | -$0.13 | |||
| Stock-based compensation | $9.22 | $10.54 | $6.96 | $0.66 |
| Total cash flows from operations | -$62.05 | -$60.08 | -$47.94 | -$14.71 |
| Investing activities | ||||
| Capital expenditures | -$10.48 | -$4.46 | -$0.94 | -$0.31 |
| Investments | $13.55 | -$12.51 | ||
| Total cash flows from investing | $3.08 | -$16.97 | -$1.82 | -$0.31 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $20.45 | $59.02 | $120.69 | $36.34 |
| Net borrowings | $0.43 | $0.46 | -$0.01 | -$4.73 |
| Total cash flows from financing | $20.88 | $59.48 | $120.68 | $31.61 |
| Effect of exchange rate | -$0.01 | $0.03 | ||
| Change in cash and equivalents | -$38.1 | -$17.55 | $70.92 | $16.6 |
News
|
State Street Corp's Strategic Acquisition of Shares in Ocugen Inc
GuruFocus.com · via Yahoo Finance
18 Oct 2024
|
|
Ocugen Inc (OCGN) Q2 2024 Earnings Call Highlights: Strategic Advances Amid...
GuruFocus.com · via Yahoo Finance
11 Oct 2024
|
|
Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year?
Zacks · via Yahoo Finance
7 Jun 2024
|
|
Ocugen (OCGN) Skyrockets 209.6% Year to Date: Heres Why
Zacks · via Yahoo Finance
23 May 2024
|
|
Ocugen (OCGN) to Report Q1 Earnings: What's in the Cards?
Zacks via Yahoo Finance
26 Apr 2024
|
|
Stockholder Alert: Robbins LLP Informs Investors of the Class Action Filed Against Ocugen, Inc....
Investing.com
11 Apr 2024
|
|
Ocugen stock gains says EU backs U.S. trial for gene therapy
Seeking Alpha
10 Apr 2024
|
|
Ocugen's gene therapy OCU400 advances in Europe
Investing.com
10 Apr 2024
|
|
Ocugen (OCGN) Up as DSMB Allows Cohort 2 Dosing in GA Study
Zacks via Yahoo Finance
8 Apr 2024
|
|
Why Ocugen Stock Is Climbing Today - Ocugen (NASDAQ:OCGN)
Benzinga
5 Apr 2024
|
Fundamentals
| Market cap | $354.12M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 290.26M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 0.59 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 2.58 |
| Quick ratio | N/A |